Core Solid Tumor
The VariantPlex Core Solid Tumor panel is a targeted next-generation sequencing (NGS) assay to detect copy number variations (CNVs), single-nucleotide variants (SNVs), insertions and deletions (indels), and microsatellite instability (MSI) status in 60 cancer-implicated genes, including non-small cell lung cancer, colorectal cancer, breast cancer, bladder cancer and melanoma. When used alongside an RNA-based FusionPlex® solid tumor panel, fusions, SNVs/indels, CNVs, MSI and RNA expression profiles can be analyzed from a single low-input FFPE sample.
Confirm relevant CNV and SNV/indel calls when using a companion FusionPlex solid tumor panel.
Create from scratch or modify any panel to keep up with the pace of discovery.
Anchored Multiplex PCR (AMP™) chemistry was purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.
Simple, Lyophilized Workflow
Easy-to-handle lyophilized reagents and a simple workflow to reduce turnaround time, as well as minimize errors and contamination risk.
60 + MSI
Input DNA Required*
Recommended # of reads
FFPE, fresh frozen, cytology smear, FNA
*Input mass requirements vary depending on type and quality. Unless the tumor cellularity and sample quality are high, 50ng of FFPE-derived nucleic acid should be considered the minimum recommendation. If input is not limiting, 200ng is recommended.